Rhythm Pharmaceuticals (RYTM) Competitors $54.54 -0.12 (-0.22%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends RYTM vs. SMMT, MRNA, ITCI, RDY, CTLT, SRPT, QGEN, PCVX, ASND, and ROIVShould you be buying Rhythm Pharmaceuticals stock or one of its competitors? The main competitors of Rhythm Pharmaceuticals include Summit Therapeutics (SMMT), Moderna (MRNA), Intra-Cellular Therapies (ITCI), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), Sarepta Therapeutics (SRPT), Qiagen (QGEN), Vaxcyte (PCVX), Ascendis Pharma A/S (ASND), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. Rhythm Pharmaceuticals vs. Summit Therapeutics Moderna Intra-Cellular Therapies Dr. Reddy's Laboratories Catalent Sarepta Therapeutics Qiagen Vaxcyte Ascendis Pharma A/S Roivant Sciences Rhythm Pharmaceuticals (NASDAQ:RYTM) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, community ranking, institutional ownership, media sentiment and risk. Does the media prefer RYTM or SMMT? In the previous week, Rhythm Pharmaceuticals had 1 more articles in the media than Summit Therapeutics. MarketBeat recorded 7 mentions for Rhythm Pharmaceuticals and 6 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.71 beat Rhythm Pharmaceuticals' score of 0.71 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Summit Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer RYTM or SMMT? Summit Therapeutics received 6 more outperform votes than Rhythm Pharmaceuticals when rated by MarketBeat users. However, 67.12% of users gave Rhythm Pharmaceuticals an outperform vote while only 58.30% of users gave Summit Therapeutics an outperform vote. CompanyUnderperformOutperformRhythm PharmaceuticalsOutperform Votes29667.12% Underperform Votes14532.88% Summit TherapeuticsOutperform Votes30258.30% Underperform Votes21641.70% Which has more volatility & risk, RYTM or SMMT? Rhythm Pharmaceuticals has a beta of 2.16, indicating that its share price is 116% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -0.87, indicating that its share price is 187% less volatile than the S&P 500. Is RYTM or SMMT more profitable? Summit Therapeutics has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -230.07%. Summit Therapeutics' return on equity of -85.42% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-230.07% -367.36% -77.47% Summit Therapeutics N/A -85.42%-52.66% Do analysts prefer RYTM or SMMT? Rhythm Pharmaceuticals presently has a consensus target price of $68.09, suggesting a potential upside of 24.85%. Summit Therapeutics has a consensus target price of $33.57, suggesting a potential upside of 76.41%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91Summit Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Which has better earnings & valuation, RYTM or SMMT? Rhythm Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$77.43M43.29-$184.68M-$4.33-12.60Summit Therapeutics$700K20,048.11-$614.93M-$0.28-67.96 Do insiders and institutionals have more ownership in RYTM or SMMT? 4.6% of Summit Therapeutics shares are owned by institutional investors. 5.6% of Rhythm Pharmaceuticals shares are owned by company insiders. Comparatively, 88.3% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummarySummit Therapeutics beats Rhythm Pharmaceuticals on 10 of the 18 factors compared between the two stocks. Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RYTM vs. The Competition Export to ExcelMetricRhythm PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.35B$6.58B$5.35B$9.06BDividend YieldN/A2.94%5.13%4.02%P/E Ratio-12.609.8389.4817.34Price / Sales43.29307.731,251.60134.53Price / CashN/A61.4443.7535.97Price / Book19.006.055.324.80Net Income-$184.68M$154.62M$122.60M$224.91M7 Day Performance-2.90%-1.70%0.88%1.90%1 Month Performance1.58%2.75%4.81%5.08%1 Year Performance33.19%2.60%27.90%21.15% Rhythm Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RYTMRhythm Pharmaceuticals4.084 of 5 stars$54.54-0.2%$68.09+24.8%+30.7%$3.35B$77.43M-12.60140SMMTSummit Therapeutics2.8416 of 5 stars$18.30+2.5%$33.57+83.5%+468.1%$13.50B$700,000.00-65.35105MRNAModerna4.7373 of 5 stars$35.04-17.1%$78.83+125.0%-66.1%$13.48B$5.06B-6.025,600Analyst ForecastOptions VolumeAnalyst RevisionNews CoverageHigh Trading VolumeITCIIntra-Cellular Therapies3.7969 of 5 stars$127.17+34.0%$97.23-23.5%+91.4%$13.48B$612.78M-146.17560Analyst ForecastHigh Trading VolumeRDYDr. Reddy's Laboratories2.0121 of 5 stars$15.33-0.6%$17.00+10.9%+10.6%$12.80B$3.35B24.4927,048News CoverageCTLTCatalent1.2524 of 5 stars$63.48flat$63.40-0.1%N/A$11.52B$4.42B-28.0916,900News CoverageSRPTSarepta Therapeutics4.9442 of 5 stars$117.73-5.7%$178.71+51.8%+0.8%$11.25B$1.64B94.181,314Analyst ForecastAnalyst RevisionNews CoverageQGENQiagen4.0945 of 5 stars$46.00+3.0%$51.50+12.0%-0.2%$10.50B$1.97B117.955,967Short Interest ↓News CoveragePCVXVaxcyte1.9841 of 5 stars$80.93-0.2%$145.71+80.0%+35.7%$10.09BN/A-17.59160Insider TradeAnalyst RevisionNews CoverageASNDAscendis Pharma A/S3.6129 of 5 stars$133.43+3.3%$192.07+43.9%-3.2%$8.10B$327.43M-16.51640Short Interest ↓ROIVRoivant Sciences3.6806 of 5 stars$10.70+0.7%$17.93+67.6%+3.6%$7.79B$129.13M1.89860Insider TradeOptions VolumePositive News Related Companies and Tools Related Companies Summit Therapeutics Competitors Moderna Competitors Intra-Cellular Therapies Competitors Dr. Reddy's Laboratories Competitors Catalent Competitors Sarepta Therapeutics Competitors Qiagen Competitors Vaxcyte Competitors Ascendis Pharma A/S Competitors Roivant Sciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RYTM) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RYTM Stock Alerts